Table 1.
Clinical trials testing perindopril and telmisartan
| Trial | Treatment | Comparator | Baseline SBP | SBP difference between arms | Total mortality benefit | CI |
|---|---|---|---|---|---|---|
| Perindopril | ||||||
| ADVANCE | Perindopril (+ indapamide) | Placebo | 145 mmHg | −5.6 mmHg | −14% | (−25; −2) |
| ASCOT | Perindopril (+ amlodipine) | Atenolol + thiazide | 164 mmHg | −2.7 mmHg | −11% | (−9; −1) |
| EUROPA | Perindopril | Placebo | 137 mmHg | −5 mmHg | −11% | (−22; +2) |
| Telmisartan | ||||||
| ONTARGET | Telmisartan (+ ramipril) | Ramipril | 142 mmHg | −2.4 mmHg | +7% | (−2; +16) |
| PROFESS | Telmisartan | Placebo | 144 mmHg | −4 mmHg | +3% | (−7; +14) |
| TRANSCEND | Telmisartan | Placebo | 141 mmHg | −4 mmHg | +5% | (−9; +22) |
Abbreviations: ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; EUROPA, European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease; ONTARGET, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial; PROFESS, Prevention Regimen for Effectively Avoiding Second Strokes; TRANSCEND, Telmisartan Randomized Assessment Study in ACE intolerant; CI, confidence interval; SBP, systolic blood pressure.